Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QLGN
DateTimeSourceHeadlineSymbolCompany
30/05/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
30/05/202421:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationNASDAQ:QLGNQualigen Therapeutics Inc
14/05/202421:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
04/05/202401:59Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
16/04/202412:00GlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
10/04/202413:00GlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
09/04/202413:00GlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
27/02/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
22/02/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
22/11/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
14/11/202321:30GlobeNewswire Inc.Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/11/202319:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/11/202313:30GlobeNewswire Inc.Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
23/10/202313:30GlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerNASDAQ:QLGNQualigen Therapeutics Inc
17/10/202313:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
28/09/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
27/09/202313:30GlobeNewswire Inc.Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/09/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
01/09/202321:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:QLGNQualigen Therapeutics Inc
17/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
15/08/202315:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
15/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023NASDAQ:QLGNQualigen Therapeutics Inc
14/08/202321:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
04/08/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
01/08/202313:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
01/08/202313:30GlobeNewswire Inc.Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
26/07/202322:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
24/07/202313:15GlobeNewswire Inc.Qualigen Therapeutics Divests FastPack® Diagnostics BusinessNASDAQ:QLGNQualigen Therapeutics Inc
13/07/202322:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QLGN

Your Recent History

Delayed Upgrade Clock